In vitro photodynamic effects of scavenger receptor targeted-photoactivatable nanoagents on activated macrophages

Yi, Bong Gu; Park, Ok Kyu; Jeong, Myeong Seon; Kwon, Soon-Jung; Jung, Jae In; Lee, Seongsoo; Ryoo, Sungwoo; Kim, Sung Eun; Kim, Jin Won; Moon, Won; Park, Kyeongsoon

doi:10.1016/j.ijbiomac.2017.01.037

Cited by 28 publications

(18 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study of macrophage-targeted theranostic nanoparticles, Yi et al [57] loaded chlorin e6 (Ce6) as a photosensitizer in their dextran sulphate-deoxycholic acid (DS-DOCA) nanomaterials. Cytotoxicity tested by methyl thiazolyl tetrazolium (MTT) indicated that Ce6/DS-DOCA-treated macrophage cells showed approximately 80% of cell deaths when compared to the non-treated macrophage (20%) after 2 minutes of laser irradiation.…”

Section: Fluorescence Based Theranostic Nanoparticles For Atherosclerosismentioning

confidence: 99%

Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Vazquez-Prada

Liu

et al. 2021

Nanotheranostics

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of death worldwide. CVD includes a group of disorders of the heart and blood vessels such as myocardial infarction, ischemic heart, ischemic injury, injured arteries, thrombosis and atherosclerosis. Amongst these, atherosclerosis is the dominant cause of CVD and is an inflammatory disease of the blood vessel wall. Diagnosis and treatment of CVD remain the main challenge due to the complexity of their pathophysiology. To overcome the limitations of current treatment and diagnostic techniques, theranostic nanomaterials have emerged. The term "theranostic nanomaterials" refers to a multifunctional agent with both therapeutic and diagnostic abilities. Theranostic nanoparticles can provide imaging contrast for a diversity of techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET) and computed tomography (CT). In addition, they can treat CVD using photothermal ablation and/or medication by the drugs in nanoparticles. This review discusses the latest advances in theranostic nanomaterials for the diagnosis and treatment of CVDs according to the order of disease development. MRI, CT, near-infrared spectroscopy (NIR), and fluorescence are the most widely used strategies on theranostics for CVDs detection. Different treatment methods for CVDs based on theranostic nanoparticles have also been discussed. Moreover, current problems of theranostic nanoparticles for CVDs detection and treatment and future research directions are proposed.

show abstract

Section: Fluorescence Based Theranostic Nanoparticles For Atherosclerosismentioning

confidence: 99%

Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Vazquez-Prada

Liu

et al. 2021

Nanotheranostics

View full text Add to dashboard Cite

show abstract

“…Photodynamic therapy (PDT) involves the combination of a photosensitising agent and external light to induce the killing of cells, via increased production of ROS such as singlet oxygen [ 100 ]. NPs of various compositions have been designed to target inflammatory macrophages via ROS [ 101 ], dectin-1 [ 102 ] and scavenger receptor-A (SR-A) [ 103 ] in vitro where upon uptake and exposure to light irradiation, induce cell death. This ‘double hit’ mechanism can allow a highly selective killing of macrophages, without damaging neighbouring cells ( Table 1 ).…”

Section: Nanoparticles As Theranostics In Cvdmentioning

confidence: 99%

Nanoparticle theranostics in cardiovascular inflammation

MacRitchie

Francesco

Ferreira

et al. 2021

Seminars in Immunology

View full text Add to dashboard Cite

Theranostics, literally derived from the combination of the words diagnostics and therapy, is an emerging field of clinical and preclinical research, where contrast agents, drugs and diagnostic techniques are combined to simultaneously diagnose and treat pathologies. Nanoparticles are extensively employed in theranostics due to their potential to target specific organs and their multifunctional capacity. In this review, we will discuss the current state of theranostic nanomedicine, providing key examples of its application in the imaging and treatment of cardiovascular inflammation.

show abstract

“…The mannosylated nanoparticles improve the delivery of siRNA into primary macrophages by 4-fold relative to the delivery of a nontargeted version of the same carrier [75]. Scavenger receptors (SRs) expressed in the activated macrophages are considered to be the most promising target biomarkers for targeted drug 5 Journal of Immunology Research delivery [76][77][78]. Lewis et al reported that glycosylated micelles competitively block macrophages SRs of MSR1 and CD36 to reduce the assimilation and accumulation of ox-LDL [79].…”

Section: Macrophages For Targetedmentioning

confidence: 99%

Macrophage-Based Therapies for Atherosclerosis Management

Peng

Jin

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Atherosclerosis (AS), a typical chronic inflammatory vascular disease, is the main pathological basis of ischemic cardio/cerebrovascular disease (CVD). Long-term administration was characterized with low efficacy and serious side effects, while the macrophages with attractive intrinsic homing target have great potential in the efficient and safe management of AS. In this review, we focused on the systematical summary of the macrophage-based therapies in AS management, including macrophage autophagy, polarization, targeted delivery, microenvironment-triggered drug release, and macrophage- or macrophage membrane-based drug carrier. In conclusion, macrophage-based therapies have great promise to effectively manage AS in future research and clinic translation.

show abstract

In vitro photodynamic effects of scavenger receptor targeted-photoactivatable nanoagents on activated macrophages

Cited by 28 publications

References 40 publications

Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Nanoparticle theranostics in cardiovascular inflammation

Macrophage-Based Therapies for Atherosclerosis Management

Contact Info

Product

Resources

About